Outcomes And Prognostic Factors Of Patients Diagnosed With High-Grade B-Cell Lymphoma, Not Otherwise Specified: A Multi-Institutional Retrospective Study Read more
An Open-Label, Phase 1/2 Study Of JCAR017 In Subjects With Relapsed Or Refractory Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma (017004) Read more
A Global Randomized Multicenter Phase 3 Trial Of JCAR017 Compared To Standard Of Care In Adult Subjects With High-Risk, Second-Line, Transplant-Eligible Relapsed Or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (TRANSFORM). Read more
Phase I/II Of Nivolumab And A(B)VD In The Front-Line Setting For High Risk Hodgkin Lymphoma Read more
A Phase II Trial Of PET-Directed Therapy Using AVD (Doxorubicin, Vinblastine, And Dacarbazine) Plus Brentuximab Vedotin Induction Chemotherapy, With Or Without Brentuximab Vedotin Plus Nivolumab, Followed By Nivolumab Consolidation For Patients With Previously Untreated Non-Bulky Limited Stage Hodgkin Lymphoma Read more
An Open Label, Compassionate Use Study Of Tenalisib (RP6530) In Patients Currently Receiving Treatment On Tenalisib Trials In Hematological Malignancies Read more
Phase I/II, Open-Label Study Of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) With Lenalidomide-R-ICE (R2-ICE) In Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Read more
A Phase 1, Multicenter, Open-Label Study Of CC-97540, CD19-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, In Subjects With Relapsed Or Refractory B-Cell Non-Hodgkin Lymphoma Read more
